FluoroPharma Medical, Inc.: 10-Q filed 2012-11-14
What FluoroPharma Medical, Inc. reported in its quarterly report filed 2012-11-14 (fiscal Q3 2012): 26 published measures, 88 facts as tagged in accession 0001415889-12-001689.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-11-14
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001415889-12-001689 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All FluoroPharma Medical, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 1,127,011 | USD | |
| At 2011-12-31 | 3,546,395 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 984,007 | USD | |
| At 2011-12-31 | 3,165,991 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 776,163 | USD | |
| At 2011-12-31 | 3,265,141 | USD | |
| At 2011-09-30 | 3,210,935 | USD | |
| At 2010-12-31 | 11,413 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -998,996 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -2,662,979 | USD | 274 |
| 2003-06-13 to 2012-09-30 | -14,559,318 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | -441,619 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,569,745 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -2,450,543 | USD | 274 |
| 2003-06-13 to 2012-09-30 | -10,329,832 | USD | 3398 |
| 2011-01-01 to 2011-09-30 | -1,569,244 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -38,435 | USD | 274 |
| 2003-06-13 to 2012-09-30 | -410,478 | USD | 3398 |
| 2011-01-01 to 2011-09-30 | -9,732 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2003-06-13 to 2012-09-30 | 11,678,013 | USD | 3398 |
| 2011-01-01 to 2011-09-30 | 4,780,929 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -38,435 | USD | 274 |
| 2003-06-13 to 2012-09-30 | -572,018 | USD | 3398 |
| 2011-01-01 to 2011-09-30 | -12,163 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | -15,660,845 | USD | |
| At 2011-12-31 | -12,873,729 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 22,443,202 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 22,407,378 | shares | 274 |
| 2003-06-13 to 2012-09-30 | 9,082,797 | shares | 3398 |
| 2011-07-01 to 2011-09-30 | 20,967,981 | shares | 92 |
| 2011-01-01 to 2011-09-30 | 16,542,270 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -0.05 | USD/shares | 92 |
| 2012-01-01 to 2012-09-30 | -0.12 | USD/shares | 274 |
| 2003-06-13 to 2012-09-30 | -1.72 | USD/shares | 3398 |
| 2011-07-01 to 2011-09-30 | -0.02 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | -0.21 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -0.05 | USD/shares | 92 |
| 2012-01-01 to 2012-09-30 | -0.12 | USD/shares | 274 |
| 2003-06-13 to 2012-09-30 | -1.72 | USD/shares | 3398 |
| 2011-07-01 to 2011-09-30 | -0.02 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | -0.21 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 180,060 | USD | |
| At 2011-12-31 | 169,808 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 890,227 | USD | |
| At 2011-12-31 | 3,315,432 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2003-06-13 to 2012-09-30 | -316,326 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | -1,005 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -113,193 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 143,004 | USD | |
| At 2011-12-31 | 380,404 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 79,533 | USD | |
| At 2011-12-31 | 341,172 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 56,724 | USD | |
| At 2011-12-31 | 61,155 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 1,008,334 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 2,796,691 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 15,792,498 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | 440,614 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 2,569,958 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 344,871 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 905,142 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 5,548,919 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | 10,272 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 255,508 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -1,041,717 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -2,787,116 | USD | 274 |
| 2003-06-13 to 2012-09-30 | -15,660,845 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | -480,228 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -3,468,608 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 448,438 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,016,322 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 5,997,079 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | 270,532 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 1,794,249 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 4,512 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 14,022 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 145,106 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | 5,811 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 17,493 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 9,338 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 133,712 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 1,233,180 | USD | 3398 |
| 2011-07-01 to 2011-09-30 | -1,005 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 213 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2003-06-13 to 2012-09-30 | 50,000 | USD | 3398 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -114,336 | USD | 274 |
| 2003-06-13 to 2012-09-30 | 591,783 | USD | 3398 |
| 2011-01-01 to 2011-09-30 | -436,361 | USD | 273 |
Inspect the source
- Entity
- FluoroPharma Medical, Inc. / CIK 0001402785
- Captured
- SEC response SHA-256
4d77d986a03178d60883d667e91c227ed829415c26872c73ee7ae0df9851ff14
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001402785.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))